Mark Nehler
Concepts (413)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 34 | 2026 | 506 | 4.230 |
Why?
| | Ischemia | 30 | 2024 | 422 | 3.830 |
Why?
| | Lower Extremity | 23 | 2026 | 440 | 2.430 |
Why?
| | Internship and Residency | 19 | 2026 | 1264 | 2.330 |
Why?
| | Rivaroxaban | 21 | 2026 | 271 | 2.200 |
Why?
| | Vascular Surgical Procedures | 26 | 2026 | 343 | 2.160 |
Why?
| | General Surgery | 12 | 2026 | 206 | 2.150 |
Why?
| | Endovascular Procedures | 12 | 2026 | 389 | 1.600 |
Why?
| | Platelet Aggregation Inhibitors | 19 | 2026 | 499 | 1.540 |
Why?
| | Leg | 14 | 2007 | 242 | 1.370 |
Why?
| | Aspirin | 17 | 2026 | 406 | 1.340 |
Why?
| | Factor Xa Inhibitors | 11 | 2026 | 194 | 1.320 |
Why?
| | Peripheral Vascular Diseases | 12 | 2022 | 104 | 1.250 |
Why?
| | Limb Salvage | 11 | 2026 | 73 | 0.990 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2023 | 228 | 0.930 |
Why?
| | Surgeons | 4 | 2021 | 340 | 0.800 |
Why?
| | Femoral Artery | 10 | 2023 | 190 | 0.770 |
Why?
| | Vascular System Injuries | 5 | 2025 | 80 | 0.760 |
Why?
| | Education, Medical, Graduate | 7 | 2026 | 562 | 0.750 |
Why?
| | Arterial Occlusive Diseases | 7 | 2008 | 90 | 0.740 |
Why?
| | Thrombosis | 6 | 2025 | 401 | 0.730 |
Why?
| | Treatment Outcome | 48 | 2026 | 11741 | 0.730 |
Why?
| | Risk Factors | 37 | 2026 | 10857 | 0.650 |
Why?
| | Career Choice | 4 | 2024 | 234 | 0.640 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 167 | 0.630 |
Why?
| | Popliteal Artery | 7 | 2023 | 62 | 0.630 |
Why?
| | Intermittent Claudication | 12 | 2022 | 122 | 0.620 |
Why?
| | Puerperal Disorders | 1 | 2020 | 36 | 0.620 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2020 | 85 | 0.600 |
Why?
| | Venous Thromboembolism | 4 | 2025 | 328 | 0.580 |
Why?
| | Personnel Selection | 3 | 2018 | 91 | 0.570 |
Why?
| | Vascular Patency | 13 | 2023 | 121 | 0.540 |
Why?
| | Time Factors | 22 | 2026 | 7107 | 0.540 |
Why?
| | Aged | 52 | 2026 | 26096 | 0.540 |
Why?
| | Humans | 121 | 2026 | 145140 | 0.540 |
Why?
| | Postoperative Complications | 12 | 2024 | 2961 | 0.530 |
Why?
| | Male | 78 | 2026 | 72664 | 0.510 |
Why?
| | Risk Assessment | 16 | 2025 | 3740 | 0.500 |
Why?
| | Coronary Artery Disease | 5 | 2024 | 747 | 0.490 |
Why?
| | Female | 73 | 2026 | 78636 | 0.490 |
Why?
| | Quality Indicators, Health Care | 3 | 2016 | 336 | 0.470 |
Why?
| | Elective Surgical Procedures | 2 | 2017 | 202 | 0.450 |
Why?
| | Middle Aged | 53 | 2026 | 36126 | 0.450 |
Why?
| | Mentors | 2 | 2020 | 216 | 0.440 |
Why?
| | Clinical Competence | 4 | 2022 | 1240 | 0.430 |
Why?
| | Arteriovenous Shunt, Surgical | 2 | 2011 | 20 | 0.410 |
Why?
| | Incidence | 11 | 2025 | 2915 | 0.400 |
Why?
| | Angioplasty, Balloon | 3 | 2023 | 94 | 0.390 |
Why?
| | Aged, 80 and over | 23 | 2026 | 8318 | 0.380 |
Why?
| | Renal Dialysis | 3 | 2013 | 466 | 0.380 |
Why?
| | Upper Extremity | 2 | 2011 | 113 | 0.370 |
Why?
| | Retrospective Studies | 28 | 2025 | 17247 | 0.370 |
Why?
| | Drug Therapy, Combination | 10 | 2026 | 1043 | 0.370 |
Why?
| | Paclitaxel | 3 | 2021 | 256 | 0.360 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.330 |
Why?
| | Kidney Failure, Chronic | 4 | 2013 | 599 | 0.320 |
Why?
| | Alprostadil | 2 | 2007 | 29 | 0.310 |
Why?
| | Medicaid | 1 | 2014 | 466 | 0.300 |
Why?
| | Activities of Daily Living | 4 | 2006 | 439 | 0.300 |
Why?
| | Adult | 35 | 2026 | 40665 | 0.290 |
Why?
| | Quality of Life | 6 | 2022 | 3194 | 0.290 |
Why?
| | Wound Healing | 5 | 2009 | 354 | 0.290 |
Why?
| | Patient Readmission | 5 | 2023 | 769 | 0.290 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 296 | 0.280 |
Why?
| | United States | 18 | 2025 | 16065 | 0.270 |
Why?
| | Curriculum | 6 | 2026 | 1067 | 0.270 |
Why?
| | Medicare | 1 | 2014 | 902 | 0.270 |
Why?
| | Drug-Eluting Stents | 2 | 2021 | 88 | 0.270 |
Why?
| | Brain Ischemia | 2 | 2022 | 359 | 0.270 |
Why?
| | Double-Blind Method | 10 | 2026 | 2057 | 0.270 |
Why?
| | Kidney Diseases | 2 | 2011 | 424 | 0.260 |
Why?
| | Comorbidity | 7 | 2017 | 1657 | 0.260 |
Why?
| | Ribs | 2 | 2016 | 35 | 0.250 |
Why?
| | Students, Medical | 2 | 2023 | 376 | 0.250 |
Why?
| | Hemorrhage | 8 | 2026 | 822 | 0.250 |
Why?
| | Computer Simulation | 1 | 2011 | 1002 | 0.240 |
Why?
| | Prodrugs | 1 | 2007 | 52 | 0.240 |
Why?
| | Decision Support Techniques | 2 | 2021 | 472 | 0.240 |
Why?
| | Stroke | 3 | 2022 | 1270 | 0.240 |
Why?
| | Surveys and Questionnaires | 10 | 2024 | 6055 | 0.240 |
Why?
| | Critical Illness | 6 | 2020 | 899 | 0.240 |
Why?
| | Myocardial Infarction | 3 | 2022 | 1210 | 0.230 |
Why?
| | Thoracic Outlet Syndrome | 2 | 2016 | 14 | 0.230 |
Why?
| | Atherosclerosis | 2 | 2020 | 409 | 0.230 |
Why?
| | Venous Thrombosis | 2 | 2025 | 195 | 0.230 |
Why?
| | Software | 1 | 2011 | 678 | 0.230 |
Why?
| | Anticoagulants | 5 | 2025 | 748 | 0.230 |
Why?
| | Neoplasms | 1 | 2021 | 2900 | 0.220 |
Why?
| | Stress, Psychological | 2 | 2026 | 1145 | 0.220 |
Why?
| | Catheterization, Peripheral | 2 | 2009 | 120 | 0.220 |
Why?
| | Professional-Family Relations | 1 | 2026 | 153 | 0.220 |
Why?
| | Graft Occlusion, Vascular | 3 | 2011 | 40 | 0.220 |
Why?
| | Femoral Vein | 3 | 2008 | 38 | 0.220 |
Why?
| | Cardiovascular Surgical Procedures | 2 | 2001 | 30 | 0.220 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1186 | 0.210 |
Why?
| | Iliac Aneurysm | 2 | 2022 | 19 | 0.210 |
Why?
| | Reoperation | 10 | 2014 | 630 | 0.210 |
Why?
| | Parental Leave | 1 | 2024 | 27 | 0.200 |
Why?
| | Carotid Stenosis | 2 | 1996 | 106 | 0.200 |
Why?
| | Urology | 1 | 2024 | 63 | 0.200 |
Why?
| | Chi-Square Distribution | 3 | 2017 | 527 | 0.200 |
Why?
| | Ultrasonography, Doppler | 2 | 2021 | 126 | 0.200 |
Why?
| | Fibrinolytic Agents | 3 | 2022 | 297 | 0.200 |
Why?
| | Acute Disease | 4 | 2021 | 1035 | 0.190 |
Why?
| | Patient Care Team | 2 | 2024 | 696 | 0.190 |
Why?
| | Diabetes Complications | 3 | 2015 | 224 | 0.190 |
Why?
| | Cranial Nerve Injuries | 1 | 2023 | 5 | 0.190 |
Why?
| | Carotid Body Tumor | 1 | 2023 | 5 | 0.190 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 92 | 0.190 |
Why?
| | Academic Medical Centers | 3 | 2017 | 552 | 0.180 |
Why?
| | Diabetic Foot | 2 | 2019 | 25 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2025 | 241 | 0.180 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 64 | 0.180 |
Why?
| | Cholesterol, LDL | 1 | 2024 | 360 | 0.180 |
Why?
| | Meditation | 1 | 2022 | 34 | 0.180 |
Why?
| | Tibial Arteries | 4 | 2008 | 13 | 0.180 |
Why?
| | Thrombolytic Therapy | 1 | 2003 | 164 | 0.170 |
Why?
| | Smoking Cessation | 2 | 2002 | 437 | 0.170 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2023 | 138 | 0.170 |
Why?
| | Blood Vessel Prosthesis | 3 | 2022 | 140 | 0.170 |
Why?
| | Heparin | 3 | 2023 | 246 | 0.170 |
Why?
| | Faculty, Medical | 1 | 2024 | 301 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 198 | 0.170 |
Why?
| | Hemostatic Techniques | 1 | 2001 | 52 | 0.160 |
Why?
| | Specialties, Surgical | 2 | 2017 | 82 | 0.160 |
Why?
| | Hospital Departments | 1 | 2020 | 9 | 0.160 |
Why?
| | Quality Improvement | 2 | 2022 | 1293 | 0.160 |
Why?
| | Outpatients | 1 | 2024 | 447 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2001 | 125 | 0.160 |
Why?
| | Suture Techniques | 1 | 2001 | 137 | 0.160 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 145 | 0.160 |
Why?
| | Hyperlipidemias | 1 | 2001 | 120 | 0.150 |
Why?
| | Forefoot, Human | 1 | 1999 | 1 | 0.150 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1546 | 0.150 |
Why?
| | Toes | 1 | 1999 | 16 | 0.150 |
Why?
| | Communication | 1 | 2026 | 973 | 0.150 |
Why?
| | Burnout, Professional | 2 | 2026 | 486 | 0.150 |
Why?
| | Mentoring | 1 | 2022 | 165 | 0.150 |
Why?
| | Logistic Models | 3 | 2017 | 2133 | 0.150 |
Why?
| | Aneurysm | 2 | 1997 | 37 | 0.150 |
Why?
| | Canagliflozin | 1 | 2019 | 10 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1325 | 0.150 |
Why?
| | Self Concept | 1 | 2021 | 253 | 0.150 |
Why?
| | Counseling | 1 | 2002 | 400 | 0.140 |
Why?
| | Walking | 4 | 2022 | 542 | 0.140 |
Why?
| | Databases, Factual | 4 | 2017 | 1488 | 0.140 |
Why?
| | Clinical Clerkship | 1 | 2020 | 109 | 0.140 |
Why?
| | Patient Selection | 4 | 2014 | 733 | 0.140 |
Why?
| | Chronic Disease | 6 | 2011 | 1806 | 0.140 |
Why?
| | Carotid Artery Diseases | 1 | 2019 | 70 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2020 | 287 | 0.140 |
Why?
| | Blood Vessels | 2 | 1998 | 167 | 0.140 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 74 | 0.140 |
Why?
| | Extremities | 2 | 2009 | 140 | 0.130 |
Why?
| | School Admission Criteria | 1 | 2018 | 35 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1742 | 0.130 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2183 | 0.130 |
Why?
| | Arm | 2 | 2004 | 110 | 0.130 |
Why?
| | Odds Ratio | 3 | 2016 | 1082 | 0.130 |
Why?
| | Arteriosclerosis | 1 | 1997 | 83 | 0.130 |
Why?
| | Exercise Therapy | 2 | 2001 | 475 | 0.130 |
Why?
| | Physician Executives | 1 | 2017 | 30 | 0.130 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 1996 | 40 | 0.130 |
Why?
| | Follow-Up Studies | 9 | 2021 | 5411 | 0.130 |
Why?
| | Cost of Illness | 1 | 2019 | 324 | 0.130 |
Why?
| | Subclavian Artery | 1 | 1997 | 28 | 0.130 |
Why?
| | Homocysteine | 1 | 1997 | 152 | 0.130 |
Why?
| | Vascular Diseases | 2 | 2015 | 252 | 0.130 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1092 | 0.120 |
Why?
| | Military Personnel | 1 | 2025 | 736 | 0.120 |
Why?
| | Hospitalization | 2 | 2025 | 2458 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 195 | 0.120 |
Why?
| | Incidental Findings | 1 | 2016 | 81 | 0.120 |
Why?
| | Vascular Malformations | 1 | 2016 | 52 | 0.120 |
Why?
| | Endarterectomy, Carotid | 2 | 2013 | 63 | 0.120 |
Why?
| | Osteotomy | 1 | 2016 | 128 | 0.110 |
Why?
| | Sepsis | 2 | 2016 | 662 | 0.110 |
Why?
| | Survival Rate | 4 | 2021 | 2087 | 0.110 |
Why?
| | Popliteal Vein | 1 | 1994 | 4 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 275 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 4 | 2021 | 968 | 0.110 |
Why?
| | Hypertension | 2 | 2001 | 1269 | 0.110 |
Why?
| | Multidetector Computed Tomography | 1 | 2014 | 40 | 0.100 |
Why?
| | Disease Progression | 3 | 2014 | 2857 | 0.100 |
Why?
| | Endarterectomy | 1 | 1993 | 5 | 0.100 |
Why?
| | Thoracotomy | 1 | 2014 | 83 | 0.100 |
Why?
| | Premedication | 1 | 1993 | 45 | 0.100 |
Why?
| | Registries | 4 | 2025 | 2401 | 0.100 |
Why?
| | Bandages | 1 | 1993 | 41 | 0.100 |
Why?
| | Surgery, Computer-Assisted | 1 | 2014 | 84 | 0.100 |
Why?
| | Multiple Trauma | 1 | 2014 | 121 | 0.100 |
Why?
| | Young Adult | 7 | 2025 | 14176 | 0.100 |
Why?
| | Recurrence | 4 | 2014 | 1134 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 943 | 0.100 |
Why?
| | Recovery of Function | 3 | 2011 | 715 | 0.090 |
Why?
| | Ulnar Artery | 1 | 1992 | 4 | 0.090 |
Why?
| | Ischemic Attack, Transient | 1 | 1993 | 71 | 0.090 |
Why?
| | Injury Severity Score | 3 | 2021 | 599 | 0.090 |
Why?
| | Research Design | 2 | 2009 | 1132 | 0.090 |
Why?
| | Life Tables | 3 | 1998 | 21 | 0.090 |
Why?
| | Radial Artery | 1 | 1992 | 75 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1415 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2014 | 172 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 1145 | 0.090 |
Why?
| | Seasons | 1 | 2014 | 538 | 0.090 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 2115 | 0.090 |
Why?
| | Fingers | 1 | 1992 | 107 | 0.090 |
Why?
| | Angiography | 2 | 2024 | 208 | 0.090 |
Why?
| | Adolescent | 8 | 2025 | 22479 | 0.090 |
Why?
| | Research Personnel | 1 | 2013 | 184 | 0.090 |
Why?
| | Oregon | 1 | 2011 | 76 | 0.090 |
Why?
| | Thrombectomy | 2 | 2003 | 78 | 0.090 |
Why?
| | Aorta, Thoracic | 1 | 2014 | 286 | 0.080 |
Why?
| | Pregnancy | 2 | 2024 | 7182 | 0.080 |
Why?
| | Prognosis | 5 | 2021 | 4310 | 0.080 |
Why?
| | Efficiency | 1 | 2011 | 103 | 0.080 |
Why?
| | Arteries | 2 | 2022 | 261 | 0.080 |
Why?
| | Catheterization | 2 | 2003 | 183 | 0.080 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2009 | 27 | 0.080 |
Why?
| | Device Approval | 1 | 2009 | 19 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3410 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2013 | 354 | 0.070 |
Why?
| | Workload | 1 | 2011 | 168 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1393 | 0.070 |
Why?
| | Risk Management | 3 | 2007 | 82 | 0.070 |
Why?
| | Disability Evaluation | 1 | 2011 | 310 | 0.070 |
Why?
| | Coated Materials, Biocompatible | 2 | 2023 | 65 | 0.070 |
Why?
| | Safety | 1 | 2011 | 357 | 0.070 |
Why?
| | Axillary Vein | 1 | 2008 | 5 | 0.070 |
Why?
| | Skin | 1 | 1993 | 753 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 442 | 0.070 |
Why?
| | Saphenous Vein | 3 | 1998 | 37 | 0.070 |
Why?
| | Global Health | 2 | 2021 | 403 | 0.070 |
Why?
| | Radiography | 4 | 2015 | 852 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2021 | 2026 | 0.070 |
Why?
| | Family Practice | 2 | 2020 | 403 | 0.070 |
Why?
| | Athletic Injuries | 1 | 2014 | 571 | 0.070 |
Why?
| | Colorado | 3 | 2016 | 4538 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2021 | 178 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2011 | 1579 | 0.060 |
Why?
| | Brachial Artery | 1 | 2008 | 208 | 0.060 |
Why?
| | Biomedical Research | 1 | 2013 | 717 | 0.060 |
Why?
| | Prevalence | 1 | 2014 | 2855 | 0.060 |
Why?
| | Iloprost | 1 | 2006 | 45 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2007 | 423 | 0.060 |
Why?
| | Exercise Test | 3 | 2011 | 626 | 0.060 |
Why?
| | Prospective Studies | 5 | 2021 | 8035 | 0.060 |
Why?
| | Carotid Artery, Internal | 2 | 1996 | 45 | 0.060 |
Why?
| | United States Department of Defense | 1 | 2025 | 23 | 0.050 |
Why?
| | Regional Blood Flow | 2 | 1999 | 514 | 0.050 |
Why?
| | Sulfonic Acids | 1 | 2004 | 14 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2009 | 773 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2578 | 0.050 |
Why?
| | Thrombophilia | 1 | 2025 | 89 | 0.050 |
Why?
| | Acetates | 1 | 2004 | 78 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2015 | 316 | 0.050 |
Why?
| | Veins | 2 | 1995 | 69 | 0.050 |
Why?
| | Specialty Boards | 1 | 2024 | 42 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 67 | 0.050 |
Why?
| | Blood Pressure | 2 | 2021 | 1778 | 0.050 |
Why?
| | Physical Exertion | 1 | 2004 | 205 | 0.050 |
Why?
| | Atherectomy | 1 | 2023 | 37 | 0.050 |
Why?
| | Forecasting | 2 | 2001 | 388 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1058 | 0.050 |
Why?
| | Survival Analysis | 2 | 2004 | 1371 | 0.050 |
Why?
| | Sexism | 1 | 2023 | 68 | 0.050 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2002 | 16 | 0.050 |
Why?
| | Preoperative Care | 2 | 2002 | 380 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 7 | 0.040 |
Why?
| | Morbidity | 1 | 2023 | 322 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2022 | 67 | 0.040 |
Why?
| | Psychomotor Performance | 1 | 2004 | 324 | 0.040 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2025 | 483 | 0.040 |
Why?
| | Societies, Medical | 2 | 2009 | 898 | 0.040 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2001 | 7 | 0.040 |
Why?
| | Vascular Neoplasms | 1 | 2001 | 18 | 0.040 |
Why?
| | Cadaver | 1 | 2022 | 311 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 820 | 0.040 |
Why?
| | Angioplasty | 1 | 2001 | 50 | 0.040 |
Why?
| | Frailty | 1 | 2024 | 203 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2004 | 718 | 0.040 |
Why?
| | Aneurysm, False | 1 | 2001 | 46 | 0.040 |
Why?
| | Equipment Failure | 1 | 2001 | 115 | 0.040 |
Why?
| | Tetrazoles | 1 | 2001 | 50 | 0.040 |
Why?
| | Habits | 1 | 2020 | 52 | 0.040 |
Why?
| | Educational Measurement | 1 | 2024 | 324 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2022 | 248 | 0.040 |
Why?
| | Heart Failure | 1 | 2014 | 2324 | 0.040 |
Why?
| | Physician's Role | 1 | 2002 | 222 | 0.040 |
Why?
| | Joint Dislocations | 1 | 2021 | 60 | 0.040 |
Why?
| | Mass Screening | 1 | 2009 | 1354 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2021 | 134 | 0.040 |
Why?
| | Empathy | 1 | 2022 | 181 | 0.040 |
Why?
| | Stents | 2 | 2022 | 561 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2928 | 0.040 |
Why?
| | Diagnostic Imaging | 3 | 2007 | 337 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.040 |
Why?
| | Artificial Limbs | 1 | 2003 | 203 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 354 | 0.040 |
Why?
| | Toe Joint | 1 | 1999 | 5 | 0.040 |
Why?
| | Radiography, Interventional | 1 | 2001 | 128 | 0.040 |
Why?
| | Pulse | 1 | 1999 | 29 | 0.040 |
Why?
| | Knee Injuries | 1 | 2021 | 122 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 87 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 229 | 0.040 |
Why?
| | Pulsatile Flow | 1 | 1999 | 61 | 0.040 |
Why?
| | Internal Medicine | 1 | 2002 | 279 | 0.040 |
Why?
| | Metatarsal Bones | 1 | 1999 | 21 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 438 | 0.040 |
Why?
| | Debridement | 1 | 1999 | 85 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2024 | 775 | 0.040 |
Why?
| | Myocardial Revascularization | 1 | 2019 | 85 | 0.040 |
Why?
| | Anxiety | 1 | 2026 | 1117 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 1998 | 38 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 96 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2018 | 116 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2019 | 208 | 0.030 |
Why?
| | Postoperative Care | 1 | 2019 | 286 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 71 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 157 | 0.030 |
Why?
| | Coronary Disease | 1 | 2000 | 381 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2023 | 767 | 0.030 |
Why?
| | Knee Joint | 1 | 2021 | 426 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1264 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 1506 | 0.030 |
Why?
| | Neck | 1 | 1997 | 108 | 0.030 |
Why?
| | Age Factors | 1 | 2004 | 3338 | 0.030 |
Why?
| | Depression | 1 | 2026 | 1537 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 862 | 0.030 |
Why?
| | Risk | 1 | 2019 | 916 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 410 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2016 | 112 | 0.030 |
Why?
| | Health Promotion | 1 | 2022 | 774 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 2016 | 105 | 0.030 |
Why?
| | Cardiology | 1 | 2019 | 360 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2021 | 426 | 0.030 |
Why?
| | Foot | 1 | 1996 | 101 | 0.030 |
Why?
| | Aortic Rupture | 1 | 1995 | 27 | 0.030 |
Why?
| | Pain Measurement | 2 | 2009 | 554 | 0.030 |
Why?
| | Aorta, Abdominal | 1 | 1995 | 52 | 0.030 |
Why?
| | Groin | 1 | 1994 | 13 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1423 | 0.030 |
Why?
| | Carotid Artery, External | 1 | 1993 | 3 | 0.030 |
Why?
| | Orthopedic Equipment | 1 | 1993 | 5 | 0.030 |
Why?
| | Venous Insufficiency | 1 | 1993 | 12 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 1994 | 125 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 218 | 0.020 |
Why?
| | Cerebral Revascularization | 1 | 1993 | 22 | 0.020 |
Why?
| | Carotid Artery, Common | 1 | 1993 | 31 | 0.020 |
Why?
| | Operative Time | 1 | 2014 | 181 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 1993 | 119 | 0.020 |
Why?
| | Ankle | 1 | 1993 | 63 | 0.020 |
Why?
| | Arteritis | 1 | 1993 | 23 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2767 | 0.020 |
Why?
| | Pressure | 1 | 1993 | 226 | 0.020 |
Why?
| | Housing | 1 | 1993 | 142 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2016 | 329 | 0.020 |
Why?
| | Longitudinal Studies | 2 | 1999 | 2949 | 0.020 |
Why?
| | Exercise | 1 | 2004 | 2191 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2876 | 0.020 |
Why?
| | Nursing Homes | 1 | 1993 | 173 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1365 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5988 | 0.020 |
Why?
| | Pain | 2 | 2009 | 781 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 62 | 0.020 |
Why?
| | Lung | 1 | 2004 | 4101 | 0.020 |
Why?
| | Pneumonia | 1 | 2016 | 635 | 0.020 |
Why?
| | Equipment Safety | 1 | 2009 | 38 | 0.020 |
Why?
| | Child | 2 | 2020 | 22670 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5886 | 0.020 |
Why?
| | Ligation | 1 | 2008 | 91 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1999 | 1922 | 0.020 |
Why?
| | Illinois | 1 | 2008 | 49 | 0.020 |
Why?
| | Smoking | 1 | 2015 | 1470 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.020 |
Why?
| | Length of Stay | 1 | 2014 | 1348 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 525 | 0.020 |
Why?
| | Cardiovascular Agents | 1 | 2009 | 166 | 0.020 |
Why?
| | Ulcer | 1 | 2007 | 37 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2008 | 248 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2009 | 250 | 0.020 |
Why?
| | Cerebral Arterial Diseases | 1 | 2007 | 50 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 739 | 0.010 |
Why?
| | Drug Carriers | 1 | 2006 | 136 | 0.010 |
Why?
| | Sterol O-Acyltransferase | 1 | 2004 | 6 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 428 | 0.010 |
Why?
| | Acetamides | 1 | 2004 | 39 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 798 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2007 | 640 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 781 | 0.010 |
Why?
| | Hemodynamics | 1 | 2009 | 1115 | 0.010 |
Why?
| | Hyperemia | 1 | 2004 | 49 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 420 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 784 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2002 | 98 | 0.010 |
Why?
| | Lipids | 1 | 2006 | 706 | 0.010 |
Why?
| | World Health Organization | 1 | 2000 | 104 | 0.010 |
Why?
| | Sulfonamides | 1 | 2004 | 583 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 221 | 0.010 |
Why?
| | Heart Function Tests | 1 | 2000 | 59 | 0.010 |
Why?
| | Algorithms | 1 | 2007 | 1845 | 0.010 |
Why?
| | Epoprostenol | 1 | 1999 | 132 | 0.010 |
Why?
| | Aneurysm, Ruptured | 1 | 1998 | 38 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2000 | 556 | 0.010 |
Why?
| | Gangrene | 1 | 1996 | 11 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2000 | 708 | 0.010 |
Why?
| | Embolization, Therapeutic | 1 | 1998 | 242 | 0.010 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 1995 | 37 | 0.010 |
Why?
| | Health Status | 1 | 2000 | 832 | 0.010 |
Why?
| | Takayasu Arteritis | 1 | 1993 | 16 | 0.010 |
Why?
| | Behcet Syndrome | 1 | 1993 | 19 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 6435 | 0.000 |
Why?
|
|
Nehler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|